121 results on '"Belderbos, José"'
Search Results
2. Baseline shift corrections towards the heart: External validation of the impact on survival in early-stage NSCLC patients
3. Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study
4. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
5. Delivered dose–effect analysis of radiation induced rib fractures after thoracic SBRT
6. Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine
7. ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer
8. Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise
9. The use of real-world evidence to audit normal tissue complication probability models for acute esophageal toxicity in non-small cell lung cancer patients
10. The prognostic value of volumetric changes of the primary tumor measured on Cone Beam-CT during radiotherapy for concurrent chemoradiation in NSCLC patients
11. The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts
12. Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC
13. Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients
14. SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial
15. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy
16. Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study
17. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
18. Pre-hydration in cisplatin-based CCRT: Effects on tumour concentrations and treatment outcome
19. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
20. Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: The impact of a local dose–effect relationship for lung perfusion loss
21. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer
22. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)
23. External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy
24. Comparison of SUVmax and SUVpeak based segmentation to determine primary lung tumour volume on FDG PET-CT correlated with pathology data
25. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II–III NSCLC
26. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer
27. Interobserver variability in the delineation of the primary lung cancer and lymph nodes on different four-dimensional computed tomography reconstructions
28. 1594: Oesophageal toxicity in the phase 2 PET-Boost dose-escalation trial (NCT01024829) in LA-NSCLC
29. 2742: Cardiac condition unchanged after SBRT near the heart for NSCLC; results of prospective HALO trial
30. 2692: Modelling lymphocyte counts of NSCLC patients during chemoradiotherapy for survival analysis.
31. 2638: Toxicity analysis of high dose re-irradiation of in-field recurrent lung cancer: a prospective trial
32. In Response to Arcidiacono et al.: “Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?”
33. Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer
34. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer
35. Dose to heart substructures is associated with non-cancer death after SBRT in stage I–II NSCLC patients
36. Dose–effect analysis of radiation induced rib fractures after thoracic SBRT
37. Effects of anatomical changes on pencil beam scanning proton plans in locally advanced NSCLC patients
38. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab
39. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy
40. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy
41. Validation of automatic segmentation of ribs for NTCP modeling
42. Fractures of thoracic vertebrae in patients with locally advanced non-small cell lung carcinoma treated with intensity modulated radiotherapy
43. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014
44. Target delineation variability and corresponding margins of peripheral early stage NSCLC treated with stereotactic body radiotherapy
45. Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy
46. Dose–response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance
47. Mid-ventilation based PTV margins in Stereotactic Body Radiotherapy (SBRT): A clinical evaluation
48. Treatment adherence in concurrent chemoradiation in patients with locally advanced non-small cell lung carcinoma: Results of daily intravenous prehydration
49. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating
50. Microscopic disease extensions as a risk factor for loco-regional recurrence of NSCLC after SBRT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.